clinical trial · NCT00821821
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
Acute Ischemic Stroke (AIS)MCI-186Placebo
brief summary
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.
started
Feb 28, 2009
primary completion
Nov 30, 2010
completion
Nov 30, 2010
last updated
Jul 16, 2026
official title
A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol